Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias

Annals of Pharmacotherapy

Volumn 32, Issue 10, 1998, Pages 1030-1043

  Yee, Helen S ^a,b,c   Fong, Nancy T ^a,b,c  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Atorvastatin; Dyslipidemia; Hypercholesterolemia

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COLESTIPOL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; DYSPEPSIA; ECONOMIC ASPECT; ENZYME INHIBITION; FLATULENCE; HUMAN; HYPERCHOLESTEROLEMIA; MYOPATHY; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; TREATMENT OUTCOME;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; PYRROLES; TREATMENT OUTCOME;

EID: 0031738761     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17231     Document Type: Review

References (99)

1. American Heart Association. 1997 heart and stroke statistical update. Dallas: American Heart Association National Center, 1996.
2. Brown MS, Goldstein JL. The hyperlipoproteinemias and other disorders of lipid metabolism. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw Hill, 1994:2058-9,2061.
3. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham Study. Arch Intern Med 1981;141:1128-31.
4. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8.
5. Carlson LA, Böttiger LE. Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm Prospective Study. Lancet 1972;1:865-8.
6. Vega GL, Grundy SM. Comparison of apolipoprotein B to cholesterol in low density lipoproteins of patients with coronary heart disease. J Lipid Res 1984;25:580-92.
7. Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management (editorial)? Arteriosclerosis 1990;10: 668-71.
8. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.
9. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 1990;301: 1248-51.
10. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis E, et al. Lipoprotein (a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994;271:999-1003.
11. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-8.
12. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Circulation 1989;79:8-15.
13. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-8.
14. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
15. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:365-74.
16. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
17. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
18. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-9.
19. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
20. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-91.
21. Aengevaeren WRM, Uijen GJH, Jukema JW, Bruschke AVG, van der Werf T. Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1997;96:429-35.
22. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
23. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-76.
24. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91: 2528-40.
25. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12.
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
27. Package insert. Baycol (cerivastatin sodium tablets). West Haven, CT: Bayer, 1997.
28. Package insert. Lescol (fluvastatin sodium capsules). East Hanover, NJ: Sandoz, 1997.
29. Package insert. Zocor (simvastatin tablets). West Point, PA: Merck & Co., Inc., 1997.
30. Package insert. Mevacor (lovastatin tablets). West Point. PA: Merck & Co., Inc., 1997.
31. Package insert. Pravachol (pravastatin sodium tablets). Princeton, NJ: Bristol-Myers Squibb Co., 1996.
32. Package insert. Lipitor (atorvastatin calcium tablets). Morris Plains, NJ: Parke-Davis, 1997.
33. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien P-J, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Aterioscler Thromb Vasc Biol 1995;15:678-82.
34. Baumann KL, Butler DE, Deering CF, Mennen KE, Millar A, Nanninga TN, et al. The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett 1992;33:2283-4.
35. Brower PL, Butler DE, Deering CF, Le TV, Millar A, Nanninga TN, et al. The synthesis of (4R-cis)-1,1-dimethyethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for the preparation of CI-981, a highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett 1992;33:2279-82.
36. Michniewicz BM, Black AE, Sinz MW, Woolf TF. In vitro and in vivo metabolism of atorvastatin (CI 981) (abstract). Sixth North American ISSX Meeting, Raleigh, VA, October 23-27, 1994. Bethesda, MD: International Society for the Study of Xenobiotics, 1994.
37. Yang B-B, Smithers JA, Stern RH, Sedman AJ, Olson SC. Pharmacokinetics and dose proportionality of atorvastatin and its active metabolites (abstract). Pharm Res 1996;13(suppl 9):437S.
38. Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, Whitfield LR. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1996;36:242-6.
39. Bocan TMA, Ferguson E, McNally W, Uhlendorf PD, Mueller SB, Dehart P, et al. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta 1992;1123:133-44.
40. Naoumova RP, Marais AD, Mountney J, Firth JC, Rendell NB, Taylor GW, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 1996;119:203-13.
41. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
42. Reihnér E, Rudling M, Ståhlberg D, Berglund L, Ewerth S, Björkhem I, et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990;323:224-8.
43. Berglund LF, Beltz WF, Elam RL, Witztum JL. Altered apolipoprotein B metabolism in very low density lipoprotein from lovastatin-treated guinea pigs. J Lipid Res 1994;35:956-65.
44. Conde K, Vergara-Jimenez M, Krause BR, Newton RS, Fernandez ML. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res 1996;37:2372-82.
45. Burnett JR, Telford DE, Kleinstiver SJ, Barett PHR, Newton RS, Huff MW. Atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs (abstract). XII International Symposium on Drugs Affecting Lipid Metabolism. November 7-10, 1995.
46. Humble E, Al-Shurbaji A, Lund E, Berglund L. Studies on rat liver phosphatidate phosphohydrolase and plasma lipids: effect of HMG-CoA reductase inhibitors. Biochim Biophys Acta 1994;1214:32-8.
47. Khan B, Wilcox HG, Heimberg M. Cholesterol is required for secretion of very-low-density lipoprotein by rat liver. Biochem J 1989;258:807-16.
48. Kasim SE, LeBoeuf RC, Khilnani S, Tallapaka L, Dayananda D, Jen K-LC. Mechanisms of triglyceride-lowering effect of HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat. J Lipid Res 1992;33:1-7.
49. Radulovic LL, Cilla DD, Posvar EL, Sedman AJ, Whitfield LR. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 1995;35:990-4.
50. Posvar EL, Radulovic LL, Cilla DD, Whitfield LR, Sedman AJ. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol 1996;36: 728-31.
51. Cilla DD, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996;60:687-95.
52. Cilla DD, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normo-cholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996;36:604-9.
53. Naoumova RP, Dunn S, Rallidis L, Abu-Muhana O, Neuwirth C, Rendell NB, et al. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res 1997;38:1496-500.
54. Gibson DM, Yang B-B, Abel RB, Blum RA, Horton M, Stern RH, et al. Effects of hepatic and renal impairment on pharmacokinetics (pk) and pharmacodynamics (pd) of atorvastatin (abstract). Pharm Res 1996;13 (suppl):428S.
55. Stern RH, Yang B-B, Horton M, Moore S, Abel RB, Olsen SC. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 1997;37:816-9.
56. Heinonen TM, Stein E, Weiss SR, McKenney JM, Davidson M, Shurzinske L, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther 1996;18:853-63.
57. Davidson MH, Nawrocki JW, Weiss SR, Schwartz SL, Lupien P-J, Jones PH, et al. Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. Am J Cardiol 1997;80:347-8.
58. Heinonen TM, Schrott H, McKenney JM, Sniderman AD, Broyles FE, Zavoral JH, et al. Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol. J Cardiovasc Pharmacol Ther 1996;1:117-22.
59. Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17:1527-31.
60. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-33.
61. McKenney JM, McCormick LS, Weiss S, Koren M, Kafonek S, Black DM for the Collaborative Atorvastatin Study Group. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Am J Med 1998;104:137-43.
62. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997;79:1475-81.
63. Bertolini S, Bon GB, Campbell LM, Farnier M, Langan J, Mahla G, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997;130:191-7.
64. Dart A, Jerums G, Nicholson G, d'Emdem M, Hamilton-Craig I, Tallis G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997;80:39-44.
65. Best JD, Nicholson GC, O'Neal DN, Kotowicz MA, Tebbutt NC, Chan K-W, et al. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diabet Nutr Metab 1996;9:74-80.
66. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
67. McCormick LS, Black DM, Waters D, Brown WV, Pitt B, for the AVERT Investigators. Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT). Am J Cardiol 1997;80:1130-3.
68. Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, et al. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1998;81:578-81.
69. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
70. Lovastatin Study Groups I through IV. Lovastatin 5-year safety and efficacy study. Arch Intern Med 1993;153:1079-87.
71. Pederson TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996;156:2085-92.
72. Manoukian AA, Bhagavan NV, Hayashi T, Nestor TA, Rios C, Scottolini AG. Rhabdomyolysis secondary to lovastatin therapy. Clin Chem 1990;36:2145-7.
73. Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 1988;260:239-41.
74. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin (letter). N Engl J Med 1988;318:46-7.
75. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264:71-5.
76. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis (letter). Ann Intern Med 1988;109:682-3.
77. Spach DH, Bauwens JE, Clark CD, Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991;154:213-5.
78. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole (letter). N Engl J Med 1995; 333:664-5.
79. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis (letter). Ann Intern Med 1988;109:597-8.
80. Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch Dermatol 1996;132:1254.
81. Segaert MF, De Soete C, Vandewiele I, Verbanck J. Drug-interaction-induced rhabdomyolysis. Nephrol Dial Transplant 1996;11:1846-7.
82. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998;158:577-84.
83. Robertson DG, Urda ER, Rothwell CE, Walsh KM. Atorvastatin is not cataractogenic in beagle dogs. Curr Eye Res 1997;16:1229-35.
84. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998;81:368-9.
85. Yang B-B, Smithers JA, Abel RB, Stern RH, Sedman AJ, Olson SC. Effects of Maalox TC on pharmacokinetics and pharmacodynamics of atorvastatin (abstract). Pharm Res 1996;13(suppl 9):437S.
86. Yang B-B, Hounslow NJ, Sedman AJ, Forgue ST. Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine. J Clin Pharmacol 1996;36:356-60.
87. Stern RH, Gibson DM, Whitfield LR. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. Eur J Clin Pharmacol 1998;53:475-8.
88. Yang B-B, Siedlik PH, Smithers JA, Sedman AJ, Stern RH. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: erythromycin and ethinyl estradiol (abstract). Pharm Res 1996;13(suppl 9): 437S.
89. Stern R, Abel R, Gibson GL, Besserer J. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol 1997;37:1062-4.
90. Walker JF. Simvastatin: the clinical profile. Am J Med 1989;87(suppl 4A):44S-6S.
91. Ahmad S. Lovastatin warfarin interaction. Arch Intern Med 1990;150: 2407.
92. Dostal LA, Schardein JL, Anderson JA. Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits. Teratology 1994;50:387-94.
93. Henck JW, Craft WR, Black A, Colgin J, Anderson JA. Pre-and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats. Toxicol Sci 1998;41:88-99.
94. Ciaravino V, Kropko ML, Rothwell CE, Hovey CA, Theiss JC. The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia. Mutat Res 1995;343:95-107.
95. Dostal LA, Whitfield LR, Anderson JA. Fertility and general reproduction studies in rats with the HMG-CoA reductase inhibitor, atorvastatin. Fundam Appl Toxicol 1996;32:285-92.
96. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, et al., for the Scandinavian Survival Study Group. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93:1796-802.
97. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H, for the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-6.
98. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-51.
99. Cardinale V, ed. 1997 Drug topics red book. Montvale, NJ: Medical Economics Data, 1997:382,388,418,490,603.